Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Karyopharm Therapeutics Inc. KPTI
$2.48
-$0.16 (-6.60%)
На 18:00, 12 мая 2023
+262.90%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
306116850.00000000
-
week52high
6.84
-
week52low
2.36
-
Revenue
157074000
-
P/E TTM
-1
-
Beta
0.06297500
-
EPS
-2.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| Barclays | Overweight | Overweight | 05 авг 2022 г. |
| Baird | Outperform | Outperform | 05 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 05 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 мар 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 04 ноя 2022 г. |
| RBC Capital | Outperform | Sector Perform | 04 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 10 янв 2023 г. |
| HC Wainwright & Co. | Buy | Buy | 10 янв 2023 г. |
| Piper Sandler | Overweight | 19 янв 2023 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Paulson Richard A. | D | 608605 | 3922 | 04 янв 2023 г. |
| Paulson Richard A. | D | 612527 | 3490 | 05 дек 2022 г. |
| Paulson Richard A. | D | 616017 | 3493 | 04 ноя 2022 г. |
| Paulson Richard A. | D | 619510 | 3488 | 04 окт 2022 г. |
| Paulson Richard A. | D | 622998 | 3463 | 08 сент 2022 г. |
| Paulson Richard A. | D | 626461 | 16 | 08 сент 2022 г. |
| Mitchener Stephen | A | 30000 | 30000 | 31 авг 2022 г. |
| Mitchener Stephen | A | 70546 | 20000 | 31 авг 2022 г. |
| Mason Michael | A | 45000 | 45000 | 31 авг 2022 г. |
| Mason Michael | A | 168509 | 30000 | 31 авг 2022 г. |
Новостная лента
Karyopharm Therapeutics, Inc. (KPTI) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 19:46
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning.
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 10:41
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.53 per share a year ago.
Karyopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma Market
Seeking Alpha
20 мар 2023 г. в 04:43
Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, there is significant optionality via expansion opportunities into new indications, starting with relapsed/refractory MDS readout in the near term.
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch
PennyStocks
10 мар 2023 г. в 13:20
Short squeeze penny stocks to watch. The post Best Penny Stocks To Buy?
Karyopharm Therapeutics, Inc. (KPTI) Q4 2022 Earnings Call Transcript
Seeking Alpha
15 февр 2023 г. в 12:10
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank Maurice Raycroft - Jefferies Nicole Gabreski - Piper Sandler & Co. Michael Ulz - Morgan Stanley Edward White - H.C. Wainwright & Co. Eric Joseph - JPMorgan Chase & Co. Operator Good day.